<code id='249792C8A6'></code><style id='249792C8A6'></style>
    • <acronym id='249792C8A6'></acronym>
      <center id='249792C8A6'><center id='249792C8A6'><tfoot id='249792C8A6'></tfoot></center><abbr id='249792C8A6'><dir id='249792C8A6'><tfoot id='249792C8A6'></tfoot><noframes id='249792C8A6'>

    • <optgroup id='249792C8A6'><strike id='249792C8A6'><sup id='249792C8A6'></sup></strike><code id='249792C8A6'></code></optgroup>
        1. <b id='249792C8A6'><label id='249792C8A6'><select id='249792C8A6'><dt id='249792C8A6'><span id='249792C8A6'></span></dt></select></label></b><u id='249792C8A6'></u>
          <i id='249792C8A6'><strike id='249792C8A6'><tt id='249792C8A6'><pre id='249792C8A6'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:941
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Rock icon Freddie Mercury pre
          Rock icon Freddie Mercury pre

          1:05InthisJuly13,1985,filephoto,singerFreddieMercuryoftheBritishrockgroupQueenperformsattheLiveAidco

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          FDA panel endorses Alnylam’s heart drug — after picking it apart

          KristofferTripplaar/SipaUSA/APAgroupofadviserstotheFoodandDrugAdministrationvotedinfavorofAlnylamPha